1
|
Shpigelman J, Blaine C, Nugent CA, Kiernan L, Cahir C, Curtain BM, Bachari A, Irfan W, O'Boyle P, O'Neill J, Daly M. Electrocardiographic predictors of response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. J Electrocardiol 2024; 84:104-108. [PMID: 38615617 DOI: 10.1016/j.jelectrocard.2024.03.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Revised: 12/06/2023] [Accepted: 03/19/2024] [Indexed: 04/16/2024]
Abstract
BACKGROUND Sacubitril/valsartan (SV) is currently recommended as a first-line therapy in patients with heart failure and reduced ejection fraction (HFrEF) due to its significant clinical and prognostic benefit; however, not all patients respond to therapy and predictors of clinical response to SV remain under-studied. AIMS To identify electrocardiographic (ECG) predictors of response to SV therapy in HFrEF patients. METHODS A retrospective analysis of a hospital heart failure registry was undertaken. Consecutive HFrEF patients (New York Heart Association class II-III) on maximal-dose SV were studied. Response to SV was defined as ≥10% relative improvement in left ventricular ejection fraction (LVEF) at 3-months post-maximal-dose therapy. Pre-therapy ECGs were retrospectively analyzed for axes and standard wave and interval durations. Logistic regression was used to estimate odds ratios and 95% confidence intervals for associations between predictors and therapeutic response. Backward stepwise regression was employed to develop a parsimonious model. RESULTS P-wave duration (PWD) 100-120 ms, PWD >120 ms, and QTc >460 ms were associated with response to SV on univariate analysis: OR 18.00 (4.45-122.90), 5.00 (1.47-20.42), and 3.10 (1.18-9.22), respectively. The preferred model that included the former two predictors in combination with pre-therapy creatinine, mineralocorticoid receptor antagonist use, and LVEF was highly selective (area under the ROC curve = 0.868). CONCLUSIONS Prolongation of both PWD and QTc interval on baseline ECG in HFrEF patients is predictive of therapeutic response to maximal-dose SV therapy and may indicate early cardiac remodeling that is highly amenable to reversal.
Collapse
Affiliation(s)
| | - Ciara Blaine
- Department of Cardiology, Connolly Hospital, Blanchardstown, Dublin, Ireland
| | - Carol-Ann Nugent
- Department of Cardiology, Connolly Hospital, Blanchardstown, Dublin, Ireland
| | - Louise Kiernan
- Department of Cardiology, Connolly Hospital, Blanchardstown, Dublin, Ireland
| | - Caitriona Cahir
- Data Science Centre, Royal College of Surgeons in Ireland, Dublin, Ireland
| | | | - Amir Bachari
- School of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Wadeed Irfan
- School of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Patrick O'Boyle
- School of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland; Department of Cardiology, Connolly Hospital, Blanchardstown, Dublin, Ireland
| | - James O'Neill
- School of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland; Department of Cardiology, Connolly Hospital, Blanchardstown, Dublin, Ireland
| | - Michael Daly
- School of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland; Department of Cardiology, Connolly Hospital, Blanchardstown, Dublin, Ireland.
| |
Collapse
|
2
|
Fabiani I, Pugliese NR, Pedrizzetti G, Tonti G, Castiglione V, Chubuchny V, Taddei C, Gimelli A, Del Punta L, Balletti A, Del Franco A, Masi S, Lombardi CM, Cameli M, Emdin M, Giannoni A. Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan. ESC Heart Fail 2023; 10:2927-2938. [PMID: 37461184 PMCID: PMC10567631 DOI: 10.1002/ehf2.14346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Accepted: 03/01/2023] [Indexed: 10/13/2023] Open
Abstract
AIMS A novel tool for the evaluation of left ventricular (LV) systo-diastolic function through echo-derived haemodynamic forces (HDFs) has been recently proposed. The present study aimed to assess the predictive value of HDFs on (i) 6 month treatment response to sacubitril/valsartan in heart failure with reduced ejection fraction (HFrEF) patients and (ii) cardiovascular events. METHODS AND RESULTS Eighty-nine consecutive HFrEF patients [70% males, 65 ± 9 years, LV ejection fraction (LVEF) 27 ± 7%] initiating sacubitril/valsartan underwent clinical, laboratory, ultrasound and cardiopulmonary exercise testing evaluations. Patients experiencing no adverse events and showing ≥50% reduction in plasma N-terminal pro-B-type natriuretic peptide and/or ≥10% LVEF increase over 6 months were considered responders. Patients were followed up for the composite endpoint of HF-related hospitalisation, atrial fibrillation and cardiovascular death. Forty-five (51%) patients were responders. Among baseline variables, only HDF-derived whole cardiac cycle LV strength (wLVS) was higher in responders (4.4 ± 1.3 vs. 3.6 ± 1.2; p = 0.01). wLVS was also the only independent predictor of sacubitril/valsartan response at multivariable logistic regression analysis [odds ratio 1.36; 95% confidence interval (CI) 1.10-1.67], with good accuracy at receiver operating characteristic (ROC) analysis [optimal cutpoint: ≥3.7%; area under the curve (AUC) = 0.736]. During a 33 month (23-41) median follow-up, a wLVS increase after 6 months (ΔwLVS) showed a high discrimination ability at time-dependent ROC analysis (optimal cut-off: ≥0.5%; AUC = 0.811), stratified prognosis (log-rank p < 0.0001) and remained an independent predictor for the composite endpoint (hazard ratio 0.76; 95% CI 0.61-0.95; p < 0.01), after adjusting for clinical and instrumental variables. CONCLUSIONS HDF analysis predicts sacubitril/valsartan response and might optimise decision-making in HFrEF patients.
Collapse
Affiliation(s)
| | | | - Gianni Pedrizzetti
- Department of Engineering and ArchitectureUniversity of TriesteTriesteItaly
- Department of Biomedical EngineeringUniversity of CaliforniaIrvineCaliforniaUSA
| | - Giovanni Tonti
- Division of Cardiology‘G. D'Annunzio’ UniversityChietiItaly
| | - Vincenzo Castiglione
- Fondazione Toscana Gabriele MonasterioPisaItaly
- ‘Health Science’ Interdisciplinary Research CenterScuola Superiore Sant'AnnaPisaItaly
| | | | | | | | - Lavinia Del Punta
- Department of Clinical and Experimental MedicineUniversity of PisaPisaItaly
| | - Alessio Balletti
- Department of Clinical and Experimental MedicineUniversity of PisaPisaItaly
| | | | - Stefano Masi
- Department of Clinical and Experimental MedicineUniversity of PisaPisaItaly
| | - Carlo Mario Lombardi
- Department of Medical and Surgical Specialties, Radiological Sciences, and Public HealthUniversity of Brescia Civil HospitalBresciaItaly
| | - Matteo Cameli
- Department of Medical Biotechnologies, Division of CardiologyUniversity of SienaSienaItaly
| | - Michele Emdin
- Fondazione Toscana Gabriele MonasterioPisaItaly
- ‘Health Science’ Interdisciplinary Research CenterScuola Superiore Sant'AnnaPisaItaly
| | - Alberto Giannoni
- Fondazione Toscana Gabriele MonasterioPisaItaly
- ‘Health Science’ Interdisciplinary Research CenterScuola Superiore Sant'AnnaPisaItaly
| |
Collapse
|
3
|
Xie X, Yang M, Xie S, Wu X, Jiang Y, Liu Z, Zhao H, Chen Y, Zhang Y, Wang J. Early Prediction of Left Ventricular Reverse Remodeling in First-Diagnosed Idiopathic Dilated Cardiomyopathy: A Comparison of Linear Model, Random Forest, and Extreme Gradient Boosting. Front Cardiovasc Med 2021; 8:684004. [PMID: 34422921 PMCID: PMC8371915 DOI: 10.3389/fcvm.2021.684004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Accepted: 06/07/2021] [Indexed: 11/13/2022] Open
Abstract
Introduction: Left ventricular reverse remodeling (LVRR) is associated with decreased cardiovascular mortality and improved cardiac survival and also crucial for therapeutic options. However, there is a lack of an early prediction model of LVRR in first-diagnosed dilated cardiomyopathy. Methods: This single-center study included 104 patients with idiopathic DCM. We defined LVRR as an absolute increase in left ventricular ejection fraction (LVEF) from >10% to a final value >35% and a decrease in left ventricular end-diastolic diameter (LVDd) >10%. Analysis features included demographic characteristics, comorbidities, physical sign, biochemistry data, echocardiography, electrocardiogram, Holter monitoring, and medication. Logistic regression, random forests, and extreme gradient boosting (XGBoost) were, respectively, implemented in a 10-fold cross-validated model to discriminate LVRR and non-LVRR, with receiver operating characteristic (ROC) curves and calibration plot for performance evaluation. Results: LVRR occurred in 47 (45.2%) patients after optimal medical treatment. Cystatin C, right ventricular end-diastolic dimension, high-density lipoprotein cholesterol (HDL-C), left atrial dimension, left ventricular posterior wall dimension, systolic blood pressure, severe mitral regurgitation, eGFR, and NYHA classification were included in XGBoost, which reached higher AU-ROC compared with logistic regression (AU-ROC, 0.8205 vs. 0.5909, p = 0.0119). Ablation analysis revealed that cystatin C, right ventricular end-diastolic dimension, and HDL-C made the largest contributions to the model. Conclusion: Tree-based models like XGBoost were able to early differentiate LVRR and non-LVRR in patients with first-diagnosed DCM before drug therapy, facilitating disease management and invasive therapy selection. A multicenter prospective study is necessary for further validation. Clinical Trial Registration:http://www.chictr.org.cn/usercenter.aspx (ChiCTR2000034128).
Collapse
Affiliation(s)
- Xiangkun Xie
- Cardiovascular Medicine Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.,Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Guangzhou, China
| | - Mingwei Yang
- Cardiovascular Medicine Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.,Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Guangzhou, China.,Cardiovascular Medicine Department, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, China
| | - Shan Xie
- Department of Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
| | - Xiaoying Wu
- Cardiovascular Medicine Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.,Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Guangzhou, China
| | - Yuan Jiang
- Cardiovascular Medicine Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.,Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Guangzhou, China
| | - Zhaoyu Liu
- Department of Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
| | - Huiying Zhao
- Department of Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
| | - Yangxin Chen
- Cardiovascular Medicine Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.,Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Guangzhou, China
| | - Yuling Zhang
- Cardiovascular Medicine Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.,Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Guangzhou, China
| | - Jingfeng Wang
- Cardiovascular Medicine Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.,Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Guangzhou, China
| |
Collapse
|